智通财经网·2025-09-22 11:45Group 1 - Pfizer (PFE.US) has agreed to acquire obesity drug development startup Metsera (MTSR.US) for approximately $4.9 billion in enterprise value to strengthen its R&D pipeline [1] - The acquisition will involve a cash payment of $47.50 per share, with an additional potential payment of up to $22.50 per share contingent on achieving three specific regulatory milestones, representing a 43% premium over Metsera's closing price last Friday [1] - Following the announcement, Metsera's pre-market shares surged by 59.72%, reaching $53.22 [1] Group 2 - Pfizer is restructuring its business post-COVID-19, focusing on unproven new drug development pipelines to replace aging products [1] - Metsera is developing several experimental weight loss drugs, including an injectable with potentially lower dosing frequency compared to leading products Wegovy and Zepbound [1] - The drug MET-233i, developed by Metsera, has shown promising results in a recent study, helping patients lose up to 8.4% of their weight in 36 days, although it is still in early development stages and years away from market availability [1] - Bloomberg industry analyst Michael Shah indicated that MET-233i "could become the most promising best-in-class drug in the obesity treatment field" [1]